Press coverage about Sunshine Heart (NASDAQ:CHFS) has trended somewhat positive on Tuesday, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sunshine Heart earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.5762038950384 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
CHFS has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Sunshine Heart from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a research note on Wednesday, December 6th. ValuEngine raised shares of Sunshine Heart from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.
Shares of Sunshine Heart (NASDAQ CHFS) traded up $0.37 on Tuesday, hitting $3.80. 4,305,000 shares of the company traded hands, compared to its average volume of 201,658. Sunshine Heart has a fifty-two week low of $2.87 and a fifty-two week high of $426.00.
In other news, major shareholder Ki Yong Choi acquired 61,645 shares of Sunshine Heart stock in a transaction that occurred on Thursday, October 12th. The shares were acquired at an average price of $0.52 per share, with a total value of $32,055.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.00% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Sunshine Heart (CHFS) Getting Somewhat Positive Media Coverage, Accern Reports” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://ledgergazette.com/2017/12/12/sunshine-heart-chfs-getting-somewhat-positive-media-coverage-accern-reports.html.
Sunshine Heart Company Profile
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with MarketBeat.com's FREE daily email newsletter.